Golden State Wealth Management LLC Sells 4,706 Shares of Johnson & Johnson (NYSE:JNJ)

Golden State Wealth Management LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 59.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,225 shares of the company’s stock after selling 4,706 shares during the quarter. Golden State Wealth Management LLC’s holdings in Johnson & Johnson were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after acquiring an additional 3,358,478 shares during the last quarter. BlackRock Inc. grew its position in shares of Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after buying an additional 777,837 shares during the last quarter. State Street Corp grew its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after buying an additional 1,084,834 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after buying an additional 265,330 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 2.1 %

JNJ stock opened at $164.66 on Thursday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The business has a fifty day moving average price of $169.71 and a 200-day moving average price of $174.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The stock has a market capitalization of $432.92 billion, a P/E ratio of 23.97, a P/E/G ratio of 3.15 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.48 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday. Citigroup cut their price objective on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. UBS Group dropped their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Wells Fargo & Company lifted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.